Minigastrin
Also known as: CCK2R targeting peptide, CP04, DOTA-MG11, DOTA-MGS5, Gastrin analogue, MG, Minigastrin, PP-F11N
Source Minigastrin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Minigastrin is a truncated gastrin peptide (typically 12‑amino‑acid fragment) that retains high affinity for CCK2 receptors. It is employed mainly as a carrier for radiolabeled isotopes in diagnostic imaging and experimental radiotherapy of CCK2‑positive tumors such as medullary thyroid carcinoma.
Mechanism of Action
Agonist of the cholecystokinin B (CCK2) receptor, stimulating intracellular calcium and cAMP pathways; used as a targeting ligand for radiolabeled imaging agents
Routes of Administration
Goals & Uses
- Tumor imagingDiagnosticModerate
- Tumor imaging / nuclear medicine diagnosticsDiagnostic ImagingModerate
- Targeted radionuclide therapy of medullary thyroid carcinomaOncology / PRRTModerate
- Small cell lung cancer targetingOncologyLow
- Therapy of gastroenteropancreatic neuroendocrine tumorsOncology / PRRTLow
- Targeted radionuclide therapyTherapeuticLow
Contraindications
- Bone marrow insufficiencyHematologicalModerate
- Severe renal impairmentOrganHighKidney function concerns
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- BreastfeedingPopulationHighPotential transfer into breast milk or insufficient safety data
- severe gastrointestinal obstructionGastrointestinalModerate
Adverse Effects
- Injection site reactionsLocalUncommon
- Radiation-induced secondary malignancyOncologicRare
- Nausea and vomitingGastrointestinalCommon
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- VomitingGastrointestinalUncommonForceful expulsion of stomach contents
- MyelosuppressionHematologicUncommon
- NephrotoxicityRenalUncommon
- Transient hypotensionCardiovascularRare
Drug Interactions
- Proton pump inhibitors / H2-receptor antagonistsLow
- Other CCK2 agonistsModerate
- Nephrotoxic agents (e.g., aminoglycosides, cisplatin, NSAIDs)High
Population Constraints
- Patients with single kidney or prior renal irradiationOrgan FunctionRelative
- Pediatric patientsAgeRelative
- Patients with prior extensive myelosuppressive therapyHematologicalRelative
Regulatory Status
- European UnionInvestigationalClinical trials ongoing for imaging of CCK2‑positive tumors
- United StatesInvestigationalInvestigational radiopharmaceuticals (e.g., 68Ga‑DOTA‑MG) under IND
- United KingdomInvestigationalNo MHRA approval; investigational use only in research settings.
No regulatory approval in any jurisdiction. Investigated in early-phase clinical trials for diagnostic and therapeutic nuclear medicine applications. Various radiolabeled minigastrin analogues have entered Phase I/II trials in Europe.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Minigastrin?
Minigastrin is a truncated gastrin peptide (typically 12‑amino‑acid fragment) that retains high affinity for CCK2 receptors. It is employed mainly as a carrier for radiolabeled isotopes in diagnostic imaging and experimental radiotherapy of CCK2‑positive tumors such as medullary thyroid carcinoma.
What is Minigastrin used for?
Minigastrin is educationally associated with: Tumor imaging, Tumor imaging / nuclear medicine diagnostics, Targeted radionuclide therapy of medullary thyroid carcinoma, Small cell lung cancer targeting, Therapy of gastroenteropancreatic neuroendocrine tumors, Targeted radionuclide therapy. Educational only — not medical advice.
How is Minigastrin administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Minigastrin?
Reported adverse effects include: Injection site reactions, Radiation-induced secondary malignancy, Nausea and vomiting, Nausea, Vomiting, Myelosuppression, Nephrotoxicity, Transient hypotension. This list is not exhaustive — consult a qualified clinician.
Who should avoid Minigastrin?
Recorded contraindications: Bone marrow insufficiency, Severe renal impairment, Pregnancy, Breastfeeding, severe gastrointestinal obstruction. Consult a qualified clinician before use.